UPTRAVI FILM-COATED TABLETS 1200MCG Singapour - anglais - HSA (Health Sciences Authority)

uptravi film-coated tablets 1200mcg

johnson & johnson international (singapore) pte ltd - selexipag - tablet, film coated - selexipag 1.2 mg

UPTRAVI FILM-COATED TABLETS 1400MCG Singapour - anglais - HSA (Health Sciences Authority)

uptravi film-coated tablets 1400mcg

johnson & johnson international (singapore) pte ltd - selexipag - tablet, film coated - selexipag 1.4 mg

UPTRAVI FILM-COATED TABLETS 1600MCG Singapour - anglais - HSA (Health Sciences Authority)

uptravi film-coated tablets 1600mcg

johnson & johnson international (singapore) pte ltd - selexipag - tablet, film coated - selexipag 1.6 mg

UPTRAVI FILM-COATED TABLETS 400MCG Singapour - anglais - HSA (Health Sciences Authority)

uptravi film-coated tablets 400mcg

johnson & johnson international (singapore) pte ltd - selexipag - tablet, film coated - selexipag 0.4 mg

UPTRAVI FILM-COATED TABLETS 600MCG Singapour - anglais - HSA (Health Sciences Authority)

uptravi film-coated tablets 600mcg

johnson & johnson international (singapore) pte ltd - selexipag - tablet, film coated - selexipag 0.6 mg

UPTRAVI FILM-COATED TABLETS 800MCG Singapour - anglais - HSA (Health Sciences Authority)

uptravi film-coated tablets 800mcg

johnson & johnson international (singapore) pte ltd - selexipag - tablet, film coated - selexipag 0.8 mg

Uptravi Union européenne - anglais - EMA (European Medicines Agency)

uptravi

janssen cilag international nv - selexipag - hypertension, pulmonary - antithrombotic agents - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii–iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease.,

UPTRAVI TABLET Canada - anglais - Health Canada

uptravi tablet

janssen inc - selexipag - tablet - 200mcg - selexipag 200mcg - vasodilating agents

UPTRAVI TABLET Canada - anglais - Health Canada

uptravi tablet

janssen inc - selexipag - tablet - 400mcg - selexipag 400mcg - vasodilating agents

UPTRAVI TABLET Canada - anglais - Health Canada

uptravi tablet

janssen inc - selexipag - tablet - 600mcg - selexipag 600mcg - vasodilating agents